Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.23.2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Jun. 30, 2022
Current assets:    
Cash and cash equivalents $ 16,036 $ 150,410
Investments in marketable debt securities 85,860  
Prepaid expenses and other 3,014 1,694
Total current assets 104,910 152,104
Long-term assets:    
Investments in marketable debt securities 16,470  
Right-of-use assets 2,054 152
Property and equipment, net 139 16
Deposits and other 148 148
Total assets 123,721 152,420
Current liabilities:    
Accounts payable 3,269 1,132
Accrued liabilities:    
Compensation and benefits 883  
Accrued clinical and other 507 1,222
Current portion of operating lease liabilities 541 108
Total current liabilities 5,200 2,462
Long term liabilities:    
Operating lease liabilities, net of current portion 1,937 80
Embedded derivative liabilities 412 407
Total liabilities 7,549 2,949
Commitments and contingencies (Notes 5 and 11)
Shareholders' equity:    
Preferred stock, $0.001 par value; 400 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 100,000 shares authorized; issued and outstanding 36,827 and 33,582 shares as of June 30, 2023 and 2022, respectively 37 34
Additional paid-in capital 377,471 358,635
Accumulated other comprehensive loss (351)  
Accumulated deficit (260,985) (209,198)
Total shareholders' equity 116,172 149,471
Total liabilities and shareholders' equity $ 123,721 $ 152,420